Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: Results of an experimental study

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 1, 2008, Pages 37-44

  Li, Peng Cheng ^a   Chen, Liang Dong ^a   Zheng, Fang ^a   Li, Yan ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Disease model; HCCLM3; Hydroxycamptothecin; Peritoneal carcinomatosis

Indexed keywords

CAMPTOTHECIN DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; HYDROXYCAMPOTOTHECIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BLOOD CELL COUNT; BLOOD EXAMINATION; BODY WEIGHT; CANCER CELL CULTURE; CARCINOMATOUS PERITONITIS; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; MALE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PERITONEAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35848950727     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0242-9     Document Type: Article

References (32)

1. Boige V, Taieb J, Hebbar M, Malka D, Debaere T, Hannoun L, Magherini E, Mignard D, Poynard T, Ducreux M (2006) Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 42:456-459
2. Cagol PP, Pasqual E, Bacchetti S (2003) Natural history of the neoplastic locoregional disease: clinical and pathological patterns. J Exp Clin Cancer Res 22(4 Suppl):1-4
3. Chen T, Chu ZH, Liu JP, Wang J, Zhao HY, Ou QJ (2005) Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma. Ai Zheng 24:1018-1022 (Article in Chinese with English abstracts and graphs)
4. Eriguchi N, Aoyagi S, Okuda K, Tamae T, Fukuda S, Kanazawa N, Hamada S, Kawabata M, Nishimura K, Kodama T (2000) Successful surgical treatment for implanted intraperitoneal metastases of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 7:520-523
5. Fu YR, Yi ZJ, Yan YR, Qiu ZY (2006) Hydroxycamptothecin-induced apoptosis in hepatoma SMMC-7721 cells and the role of mitochondrial pathway. Mitochondrion 6:211-217
6. Gornet JM, Azoulay D, Duclos-Vallee JC, Goldwasser F (2000) Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. Anticancer Drugs 11:649-652
7. Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P (1998) Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 42:165-170
8. Kosaka A, Hayakawa H, Kusagawa M, Takahashi H, Okamura K, Mizumoto R, Katsuta K (1999) Successful surgical treatment for implanted intraperitoneal metastases of ruptured small hepatocellular carcinoma: report of a case. Surg Today 29:453-457
9. Li Y, Tang ZY, Ye SL, Liu BB, Liu YK, Chen J, Xue Q (2003) Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screen for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 129:43-51
10. Ministry of Health of the People's Republic of China. (2005) China's Health Statistics Overview in 2005. See the website of China's Ministry of Health at http://www.moh.gov.cn/open/statistics/digest05/s79.htm
11. Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT (1988) Potentially curative surgery of colon cancer: patterns of failure and survival. J Clin Oncol 6:106-118
12. Ohashi N, Kodera Y, Nakanishi H, Yokoyama H, Fujiwara M, Koike M, Hibi K, Nakao A, Tatematsu M (2005) Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 27:637-644
13. O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP, Saltz LB (2001) A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 91:101-105
14. Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T (2006) Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer 6:162
15. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789-802
16. Rosen LS (1998) Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Williston Park) 12(8 suppl 6):103-109
17. Rufian S, Munoz-Casares FC, Briceno J, Diaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo M, Aranda E, Muntane J, Pera C (2006) Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94:316-324
18. Ryu JK, Lee SB, Kim KH, Yoh KT (2004) Surgical treatment in a patient with multiple implanted intraperitoneal metastases after resection of ruptured large hepatocellular carcinoma. Hepatogastroenterology 51:239-242
19. Sato M, Tokui K, Watanabe Y, Lee T, Kohtani T, Nezu K, Kawachi K, Kito K, Sugita A, Ueda N. G (1999) Generalized intraperitoneal seeding of hepatocellular carcinoma after microwave coagulation therapy: a case report. Hepatogastroenterology 46:2561-2564
20. Singhal P, Lele S (2006) Intraperitoneal chemotherapy for ovarian cancer: where are we now? J Natl Compr Canc Netw 4:941-946
21. Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M (1996) Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 5:585-591
22. Sugarbaker PH, Yu W, Yonemura Y (2003) Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 21:233-248
23. Trimble EL, Alarez RD (2006) Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol 103:S18-19
24. Wall ME, Wani MC (1995) Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award lecture. Cancer Res 55:753-760
25. Ye M, Lin XX, Pan HM, Li N, Lou F, Jin W, Zheng Y,Wu JM (2005) Pharmacokinetic study of intraperitoneal chemotherapy with HCPT. Zhongguo Zhong Yao Za Zhi 30:1610-1612 (in Chinese with abstract in English)
26. Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T (2006) Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol 32:602-606
27. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to respectable gastric cancer. Ann Surg 228:374-354
28. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH (2001) Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 25:985-900
29. Yu ZJ, Yu JW, Cai W, Yuan HX, Li XY, Yuan Y, Chen JP, Wu XY, Yao DF (2005) Evaluation of HCPT d1, d14-bouble passaged intervening chemotherapy protocol for hepatocellular carcinoma. World J Gastroenterol 11:5221-5225
30. Zhang XW, Xu B (2000) Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin- induced apoptosis in Hep G2 cells. Anticancer Drugs 11:747-756
31. Zhang XW, Qing C, Xu B (1999) Apoptosis induction and cell cycle perturbation in human hepatoma hep G2 cells by 10-hydroxycamptothecin. Anticancer Drugs 10:569-576
32. Zhang XW, Zhou Y, Xu B (2000) Differentiation of human hepatoma Hep G2 cells induced by 10-hydroxycamptothecin. Chin Med J 113:712-713